Rising demand for gene and cell therapies, expanding mRNA vaccine pipelines, and increasing investments in GMP-compliant manufacturing facilities are driving growth in the viral vectors and plasmid ...
The viral vector and plasmid DNA manufacturing market is driven by the growing requirement of specialized therapies, such as gene therapies and vaccines. The growing prevalence of genetic disorders ...
According to Precedence Research, the global viral vectors & plasmid DNA manufacturing market size was estimated at USD 6.26 billion in 2024 and is expected to hit around USD 23.7 billion by 2033, ...
ROCKVILLE, Md.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) and the Gates Institute at the University of Colorado Anschutz Medical Campus today announced a lentiviral ...
Projected Growth: Viral Vectors and Plasmid DNA Manufacturing Market Set to Soar by 2033 | Market.us
An Increase in Demand and Opportunities for the Global Viral Vectors and Plasmid DNA Manufacturing Market by 2024,” offers a comprehensive analysis of the market by evaluating research and information ...
After charting multiple personalized medicine expansions in recent years, contract manufacturer Charles River Laboratories is back with another gene therapy pact—this time centered on an ...
AstraZeneca has filed a patent for technologies enhancing AAV vector production. The claim specifies a Rep/Helper plasmid with a specific polynucleotide sequence, excluding a cap gene. GlobalData’s ...
DUBLIN--(BUSINESS WIRE)--The "Viral Vectors & Plasmid DNA Manufacturing Market Report 2024-2034" report has been added to ResearchAndMarkets.com's offering. Overall world revenue for the viral vectors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback